Breast Cancer

Treatment with the combination of NGC-Cap may increase the cancer-killing power of treatment without adding significant safety concerns.

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

I usually write about my daughter’s cancer, but my friend’s stage 4 breast cancer journey showed me the limits of strength and the need for help.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.

Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.

Adding radiation before surgery with Keytruda increased immune cells in tumors and led to encouraging responses in people with early-stage breast cancer.

Tecentriq numerically increased the rates of chemotherapy-induced ovarian failure compared with chemotherapy alone for patients with triple-negative breast cancer.

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast cancer after initial therapy.

Giredestrant generated improved outcomes over standard endocrine therapy in patients with ER+/HER2–, medium- and high-risk early breast cancer.

Progression-free survival was not statistically significant with Trodelvy versus chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

After cancer, even your closet tells a story you never imagined living. One quiet afternoon, that story took a hilarious and unexpected turn.

I’ve lived with stage 4 breast cancer for 11 years, and each day brings gratitude for my family, my oncologist, and the care that keeps me going.

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so severe that she was unable to walk.

A stamp on my Christmas cards stirred deep memories and reminded me that small actions can make a meaningful impact in the fight against breast cancer.

Only 5% to 10% of breast cancers are caused by inherited gene mutations like BRCA1 or BRCA2. I do not carry one. But my family history was enough.

CURE discussed the regional anesthesia technique known as PEC I and II blocks with breast surgeon Dr. Christopher M. McGreevy.

Hearing the words “you have cancer” while carrying a baby felt like my whole world stopped.

As we’re about to celebrate Thanksgiving 2025, I’d like to honor someone for whom I’m grateful – my son, Thomas. 

Triple-negative breast cancer often needs chemotherapy, surgery, radiation or immunotherapy, and early diagnosis can support strong outcomes.